Benefits of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) on Symptoms and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease (COPD) in the ETHOS Trial

被引：0

作者：

Martinez, F. J. ^{[1
]}

Rabe, K. F. ^{[2
,3
]}

Ferguson, G. T. ^{[4
]}

Wedzicha, J. A. ^{[5
]}

Trivedi, R. ^{[6
]}

St Rose, E. ^{[7
]}

Ballal, S. ^{[7
]}

Darken, P. ^{[7
]}

Aurivillius, M. ^{[8
]}

Dorinsky, P. ^{[6
]}

Reisner, C. ^{[7
]}

机构：

[1] Weill Cornell Med, Joan & Sanford I Weill Dept Med, New York, NY USA

[2] LungenClin Grosshansdorf GmbH, Grosshansdorf, Germany

[3] Christian Albrechts Univ Kiel, Airway Res Ctr North, German Ctr Lung Res DZL, Grosshansdorf, Germany

[4] Pulm Res Inst Southeast Michigan, Farmington Hills, MI USA

[5] Imperial Coll London, Natl Heart & Lung Inst, London, England

[6] AstraZeneca, Durham, NC USA

[7] AstraZeneca, Morristown, NJ USA

[8] AstraZeneca, Gothenburg, Sweden

来源：

关键词：

D O I：

暂无

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

A5073

引用

页数：1